MolecularMD Announces Presentations at Four Upcoming Scientific Conferences
06. November 2013 07:00 ET
|
MolecularMD
PORTLAND, OR--(Marketwired - Nov 6, 2013) - MolecularMD Corp., a molecular diagnostics company focused on providing the highest quality companion diagnostics and clinical trials support services to...
MolecularMD Announces Presentations at Upcoming AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics
17. Oktober 2013 07:00 ET
|
MolecularMD
PORTLAND, OR--(Marketwired - Oct 17, 2013) - MolecularMD Corp., a molecular diagnostics company focused on providing the highest quality companion diagnostics and clinical trials support services to...
Glenn Miller, Ph.D., Joins MolecularMD as Chief Technology Officer and Executive Vice President
08. August 2013 08:05 ET
|
MolecularMD
PORTLAND, OR--(Marketwired - Aug 8, 2013) - MolecularMD Corporation today announced that Dr. Glenn Miller has been appointed to the executive management team as Chief Technology Officer and...
MolecularMD Corp. Obtains License to Commercialize Predictive Diagnostic Based on Actionable Biomarker, DDR2, for Uses in Lung Cancer and Targeted Kinase Therapy
29. Juli 2013 08:05 ET
|
MolecularMD
PORTLAND, OR--(Marketwired - Jul 29, 2013) - MolecularMD Corp. announced today that it has entered into a license agreement granting the company exclusive patent rights to cancer diagnosis...
MolecularMD Corp. Obtains Exclusive License to Uses of FGFR2 Activating Mutations in Endometrial Cancer
30. Mai 2013 08:10 ET
|
MolecularMD
PORTLAND, OR--(Marketwired - May 30, 2013) - MolecularMD Corp. announced today that it has entered into a license agreement granting the company exclusive patent rights to cancer diagnosis...
MolecularMD Corp. Offers Testing Services for Determining LKB1 Mutation and Expression Status
09. April 2013 08:15 ET
|
MolecularMD
PORTLAND, OR--(Marketwired - Apr 9, 2013) - MolecularMD Corp. announced today that it has developed and clinically validated assays for determining LKB1 mutation and expression status in patient...
MolecularMD Announces Launch of Next Generation Sequencing Services for Oncology Drug Development
04. April 2013 07:45 ET
|
MolecularMD
PORTLAND, OR--(Marketwired - Apr 4, 2013) - Today MolecularMD Corp. announced the launch of its next generation sequencing (NGS) services designed to support MolecularMD's pharmaceutical and...
MolecularMD Corp. Obtains Exclusive License to LKB1 Uses in Non-Small Cell Lung Cancer
28. Januar 2013 08:30 ET
|
MolecularMD
PORTLAND, OR--(Marketwire - Jan 28, 2013) - MolecularMD Corp. announced today that it has entered into a license agreement granting the company exclusive patent rights to cancer diagnosis...
MolecularMD and Ventana Medical Systems, Inc. Reach Collaborative Research Agreement: Limits of Detection and Sensitivity for PTEN Gene Using In-Situ Hybridization and Immunohistochemistry Methods
06. Dezember 2012 11:41 ET
|
MolecularMD
PORTLAND, OR--(Marketwire - Dec 6, 2012) - MolecularMD, based in Portland, OR, has formed a collaborative research agreement with Ventana Medical Systems, Inc. (Ventana), a member of the Roche...
MolecularMD Announces Next Generation Sequencing Presentation at Upcoming American Society of Hematology Annual Meeting
06. Dezember 2012 11:31 ET
|
MolecularMD
PORTLAND, OR--(Marketwire - Dec 6, 2012) - MolecularMD Corp. announced today that it will present data at the annual meeting of the American Society of Hematology conference, pertaining to the...